Navigation Links
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
Date:9/5/2012

ooking" statements, including, without limitation, statements related to the timing and trial design for R343 and R333 and Rigel's future product candidate pipeline and strategy. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "will," "may," "potential," "expects," "suggests," "designed," "aims," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, market competition, Rigel's need for additional capital, risks associated with Rigel's corporate partnerships and collaborations, including risks that if conflicts arise between Rigel's and its corporate partners, the clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email:

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 02, 2015 Research and ... the "Europe Ultrasound Devices Market - Growth, Trends ... offering. Currently, the European market is dominated ... of France and ... increasing incidences of chronic diseases in these regions. ...
(Date:6/3/2015)... , June 3, 2015 TWi ... that it has received final approval from the ... its Abbreviated New Drug Application (ANDA) for Guanfacine ... Pharmaceutical,s Intuniv®.  TWI,s marketing partner, Par Pharmaceuticals, will ... Intuniv® is indicated for the treatment ...
(Date:6/2/2015)... Calif. , June 2, 2015 Nevro ... company that is providing innovative evidence-based solutions for the ... an upsized underwritten public offering of its common stock ... before underwriting discounts. The offering consists of 1,764,705 shares ... be sold by certain of its stockholders, resulting in ...
Breaking Medicine Technology:European Ultrasound Devices Market Report 2015-2019 2Nevro Announces Pricing of Upsized Public Offering of Common Stock 2Nevro Announces Pricing of Upsized Public Offering of Common Stock 3
... the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & ... lawsuit against DePuy Orthopaedics, Inc. and Johnson and Johnson (NYSE: ... recalled over 90,000 ASR XL Acetabular hip replacement Systems. The ... hip replacement surgery. DePuy and Johnson and ...
... At a special meeting today, Penwest Pharmaceuticals (Nasdaq: ... West Acquisition Corp., an indirect wholly owned subsidiary of Endo ... Penwest and voted to approve the "Agreement and Plan of ...   The merger became effective on Nov. 4, ...
Cached Medicine Technology:
(Date:6/3/2015)... panel of independent experts has spent weeks considering the ... awards presented tonight at TU-Automotive Detroit 2015. , Naturally, ... can now be revealed as: , Car Maker of ... aside by taking the coveted Car Maker of the ... of expert judges., Stand out comments included: , ...
(Date:6/3/2015)... PA (PRWEB) June 03, 2015 Sitting ... can cause discomfort in the back, neck, shoulders and/or ... other musculoskeletal injuries. In addition, recent research links sitting ... number of chronic diseases. Fortunately, three inventors from Oakville, ... sit at a desk. , They have developed a ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Acne is ... (“bacne”) can be particularly stubborn to eliminate and hard to ... most common in teens and young adults, in the years ... produce sebum, or oil,” says Jayme Bashian, director and lead ... characteristic pimples, blackheads and cysts of acne are caused by ...
(Date:6/3/2015)... These are challenging and unpredictable times for ... of digital-first business are rewriting the rules for business ... need for traditional businesses to take on a more ... their services. On top of this there is ... start-ups, to bring new innovation and approaches to business. ...
(Date:6/3/2015)... 2015 “ Scanalytics ” was featured ... which features the latest and coolest technology products available ... host of NewsWatch, conducted the review and shared with ... traffic in retail stores. , Tracking statistics in business ... it comes to retail this goes a step beyond ...
Breaking Medicine News(10 mins):Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Technology to Analyze Foot Traffic in Retail Stores was featured on NewsWatch Television 2
... March 18 Askesis Development Group, Inc., a ... addictions treatment, and social services markets, is pleased ... and enhanced features are focused on creating a ... a comprehensive electronic medical record (EMR), and streamlined ...
... of certain cytokines spiked during disease stage , , WEDNESDAY, ... recently had the rare opportunity to follow the West ... in a 29-year-old lab worker who had accidentally jabbed ... researchers followed the trajectory of cytokines, a type of ...
... Institute of Technology are opening a new center that ... resonance imaging scanner to further study into the mysteries ... Advanced Brain Imaging, a joint venture of Georgia State ... topics from autism and learning disabilities, to applied physiology, ...
... disease recurrence, death nearly twice that of normal-weight patients ... cancer patients are more likely than non-obese patients to ... say U.S. researchers. , "We identified a subset ... at 12-fold increased risk of lymph node metastasis compared ...
... CEO until Executive Search for Replacement is CompletedPlanned ... 2009 at 4:15 PM ET LIVINGSTON, N.J., ... Board: MLSS), the recognized leader in advanced injection ... the Board, will temporarily assume the post of ...
... 18 The American Academy of Nurse Practitioners (AANP) ... position of AANP Chief Executive Officer, effective March 20, ... FAANP, who will retire after 13 years as CEO ... will continue in her role as Executive Director of ...
Cached Medicine News:Health News:Askesis Development Group, Inc. Launches New Behavioral Health Software for Electronic Medical Records (EMR) and Practice Management 2Health News:Course of West Nile Infection Charted 2Health News:Course of West Nile Infection Charted 3Health News:Georgia State/Georgia Tech Center for Advanced Brain Imaging to expand brain, mind research 2Health News:Obesity Tied to Poor Pancreatic Cancer Surgery Outcomes 2Health News:Milestone Scientific Announces Resignation of CEO 2Health News:Milestone Scientific Announces Resignation of CEO 3Health News:American Academy of Nurse Practitioners Announces New Chief Executive Officer 2
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... the user to quickly and accurately count bacteria ... counting or manual counting. An optional 1.5X auxiliary ... to 3.0X. The adjustable focusing rod allows the ... The lens also rotates a full 360 for ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: